Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Filomena Caiaffa

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
The World Allergy Organization Journal|January 26, 2026
Clinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE studyGiorgio Walter Canonica, Gianenrico Senna, Luisa Brussino, et al.
ERJ Open Research|February 18, 2026
Former smokers with severe eosinophilic asthma respond to benralizumab as effectively as never-smokers: a <i>post hoc</i> analysis of the ANANKE studyGianenrico Senna, Luisa Brussino, Maria Aliani, et al.
Respiratory Research|May 20, 2023
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE studyAlessandra Vultaggio, Maria Aliani, Elena Altieri, et al.
Respiration; International Review of Thoracic Diseases|April 10, 2026
Sex comparison in clinical presentation, response, and remission in severe type-2 asthma patients treated with biologics: a real-world analysis from the "Southern Italy Network on Severe Asthma Therapy"Giulia Scioscia, Carla Maria Irene Quarato, Alida Benfante, et al.
Frontiers in Medicine|September 19, 2022
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study <i>post hoc</i> analysisCristiano Caruso, Paolo Cameli, Elena Altieri, et al.
Frontiers in Allergy|June 30, 2022
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study <i>post-hoc</i> AnalysisMaria D'Amato, Francesco Menzella, Elena Altieri, et al.
Respiratory Research|February 20, 2022
ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE studyFrancesco Menzella, Elena Bargagli, Maria Aliani, et al.
Journal of Asthma and Allergy|November 17, 2022
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm<sup>3</sup>: A Post Hoc Analysis from the ANANKE StudyGianenrico Senna, Maria Aliani, Elena Altieri, et al.
Respirology (Carlton, Vic.)|June 7, 2024
Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposisCorrado Pelaia, Claudia Crimi, Alida Benfante, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 28, 2024
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M StudyClaudia Crimi, Santi Nolasco, Alberto Noto, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
The World Allergy Organization Journal|January 26, 2026
Clinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE studyGiorgio Walter Canonica, Gianenrico Senna, Luisa Brussino, et al.
ERJ Open Research|February 18, 2026
Former smokers with severe eosinophilic asthma respond to benralizumab as effectively as never-smokers: a <i>post hoc</i> analysis of the ANANKE studyGianenrico Senna, Luisa Brussino, Maria Aliani, et al.
Respiratory Research|May 20, 2023
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE studyAlessandra Vultaggio, Maria Aliani, Elena Altieri, et al.
Respiration; International Review of Thoracic Diseases|April 10, 2026
Sex comparison in clinical presentation, response, and remission in severe type-2 asthma patients treated with biologics: a real-world analysis from the "Southern Italy Network on Severe Asthma Therapy"Giulia Scioscia, Carla Maria Irene Quarato, Alida Benfante, et al.
Frontiers in Medicine|September 19, 2022
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study <i>post hoc</i> analysisCristiano Caruso, Paolo Cameli, Elena Altieri, et al.
Frontiers in Allergy|June 30, 2022
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study <i>post-hoc</i> AnalysisMaria D'Amato, Francesco Menzella, Elena Altieri, et al.
Respiratory Research|February 20, 2022
ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE studyFrancesco Menzella, Elena Bargagli, Maria Aliani, et al.
Journal of Asthma and Allergy|November 17, 2022
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm<sup>3</sup>: A Post Hoc Analysis from the ANANKE StudyGianenrico Senna, Maria Aliani, Elena Altieri, et al.
Respirology (Carlton, Vic.)|June 7, 2024
Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposisCorrado Pelaia, Claudia Crimi, Alida Benfante, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 28, 2024
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M StudyClaudia Crimi, Santi Nolasco, Alberto Noto, et al.
Pageof 5